<code id='5922B3B04B'></code><style id='5922B3B04B'></style>
    • <acronym id='5922B3B04B'></acronym>
      <center id='5922B3B04B'><center id='5922B3B04B'><tfoot id='5922B3B04B'></tfoot></center><abbr id='5922B3B04B'><dir id='5922B3B04B'><tfoot id='5922B3B04B'></tfoot><noframes id='5922B3B04B'>

    • <optgroup id='5922B3B04B'><strike id='5922B3B04B'><sup id='5922B3B04B'></sup></strike><code id='5922B3B04B'></code></optgroup>
        1. <b id='5922B3B04B'><label id='5922B3B04B'><select id='5922B3B04B'><dt id='5922B3B04B'><span id='5922B3B04B'></span></dt></select></label></b><u id='5922B3B04B'></u>
          <i id='5922B3B04B'><strike id='5922B3B04B'><tt id='5922B3B04B'><pre id='5922B3B04B'></pre></tt></strike></i>

          Home / knowledge / explore

          explore


          explore

          author:hotspot    Page View:44418
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In